 |
11 Diseases |  |
10 Trials |
|
10 Trials |  |
362 News |  |
| «1234» |
- |||||||||| Solymbic (adalimumab biosimilar) / Amgen, Amjevita (adalimumab-atto) / Amgen, Daiichi Sankyo
New P3 trial: A Comparative Study Between ABP 501 and Humira (clinicaltrials.gov) - Oct 10, 2021
P3, N=414, Not yet recruiting, Sponsor: Amgen
- | Journal: Ozanimod (Zeposia) for ulcerative colitis. (Pubmed Central) - Oct 7, 2021
No abstract available
- ||| Solymbic (adalimumab biosimilar) / Amgen, Amjevita (adalimumab biosimilar) / Amgen, Daiichi Sankyo, Ixifi (infliximab biosimilar) / Pfizer, Novartis
In Edinburgh we have been early adopters of biosimilars • CT-P13 infliximab from 2015 • SB5 & ABP501 adalimumab from 2018 • zessly / ixifi infliximab from 2020 This has saved many £££'s which we have • re-invested in service • used to spend on other biologics (Twitter) - Oct 1, 2021
- || Clinical data, Review, Journal: Efficacy and Safety of Adalimumab Biosimilars: Current Critical Clinical Data in Rheumatoid Arthritis. (Pubmed Central) - Sep 22, 2021
Overall, these biosimilars showed similar efficacy, safety, and immunogenicity to adalimumab. All biosimilar switching trials indicated that switching from adalimumab to a biosimilar does not have a significant impact on efficacy, safety, and immunogenicity.
- Humira (adalimumab) / Eisai, AbbVie
[VIRTUAL] Are Comorbidities in Patients with Chronic Inflammatory Rheumatic Diseases Associated with Treatment Adherence to Biosimilars in a Non-medical Switch Scenario? () - Sep 21, 2021 - Abstract #ACRCONVERGENCE2021ACR_CONVERGENCE_522;
This comprised 23 patients with rheumatoid arthritis (RA), 68 with axial spondyloarthritis (axSpA), and 15 with psoriatic arthritis (PsA). More than half of the patients (62%) had a Charlson comorbidity score of zero, though there were differences between disease subtypes.
- | Humira (adalimumab) / Eisai, AbbVie
Retrospective data, Journal: Ophthalmic use of TNFα inhibitor: adalimumab treatment in uveitis (Pubmed Central) - Sep 1, 2021
Orv Hetil. 2021; 162(34): 1370-1375.
- ||||| Amjevita (adalimumab-atto) / Amgen, Daiichi Sankyo
New P4 trial: A study comparing two different therapeutic approaches in the treatment of moderate to severe ulcerative colitis. Comparaci (EUDRACT) - Aug 12, 2021
P4, N=350, Ongoing, Sponsor: Instituto Clinico Humanitas
- || Solymbic (adalimumab biosimilar) / Amgen, Amjevita (adalimumab biosimilar) / Amgen, Daiichi Sankyo, Imraldi (adalimumab biosimilar) / Biogen, Merck (MSD), Samsung, Mundipharma
Clinical, Journal: Switching from Biosimilar to Biosimilar Adalimumab, Including Multiple Switching, in Crohn's Disease: A Prospective Study. (Pubmed Central) - Aug 8, 2021
We conducted a prospective, single-centre observational study in which we consecutively recruited all CD patients who switched from adalimumab biosimilar ABP 501 to biosimilar SB5 from January to July 2021...Seven patients (11.5%) experienced side effects, compared to one patient (1.6%) in the 6 pre-switch months (p = 0.03). In conclusion, switching from biosimilar to biosimilar of adalimumab did not lead to signs of safety or loss of efficacy other than those already known in the literature for the class of drugs.
- || Solymbic (adalimumab biosimilar) / Amgen, Amjevita (adalimumab biosimilar) / Amgen, Daiichi Sankyo
Clinical, Journal: A propensity score-weighted comparison between adalimumab originator and its biosimilars, ABP501 and SB5, in inflammatory bowel disease: a multicenter Italian study. (Pubmed Central) - Aug 6, 2021
Adalimumab biosimilars seem to be as effective and safe as the originator in patients with IBD. Surely, they represent a great opportunity to reduce the costs of biological therapies, however larger and longer real-life studies are necessary.
- Imraldi (adalimumab biosimilar) / Biogen, Merck (MSD), Samsung, Mundipharma, Humira (adalimumab) / Eisai, AbbVie
[VIRTUAL] LONG-TERM OUTCOMES FOLLOWING A SWITCH FROM ORIGINATOR ADALIMUMAB TO THE BIOSIMILAR SB5 (IMRALDI) IN IBD (Poster Exhibition) - Jul 20, 2021 - Abstract #UEGW2021UEGW_4585;
The most common adverse event was injection site pain; these patients were successfully moved on to Amgevita providing the first data about a double biosimilar switch. Over the 24 months of this biosimilar ADA program substantial cost savings were effected.
- Humira (adalimumab) / Eisai, AbbVie
[VIRTUAL] COMPARATIVE ASSESSMENT OF ADALIMUMAB TROUGH LEVELS BETWEEN POINT-OF-CARE TESTING AND CURRENT STANDARD OF CARE (ENZYME LINKED IMMUNOSORBENT ASSAY) IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE (Poster Exhibition) - Jul 20, 2021 - Abstract #UEGW2021UEGW_4433;
The ProciseDx POCT has similar accuracy but was more rapid and easy to be performed in providing the results of TDM in outpatients taking ADL. This could lead to a more rapid and effective optimization of the biological drug, thus avoiding treatment failure.
- Imraldi (adalimumab biosimilar) / Biogen, Merck (MSD), Samsung, Mundipharma, Humira (adalimumab) / Eisai, AbbVie
[VIRTUAL] LONG-TERM OUTCOMES FOLLOWING A SWITCH FROM ORIGINATOR ADALIMUMAB TO THE BIOSIMILAR SB5 (IMRALDI) IN IBD (Poster Exhibition) - Jul 20, 2021 - Abstract #UEGW2021UEGW_2405;
The most common adverse event was injection site pain; these patients were successfully moved on to Amgevita providing the first data about a double biosimilar switch. Over the 24 months of this biosimilar ADA program substantial cost savings were effected.
- Humira (adalimumab) / Eisai, AbbVie
[VIRTUAL] COMPARATIVE ASSESSMENT OF ADALIMUMAB TROUGH LEVELS BETWEEN POINT-OF-CARE TESTING AND CURRENT STANDARD OF CARE (ENZYME LINKED IMMUNOSORBENT ASSAY) IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE (Poster Exhibition) - Jul 20, 2021 - Abstract #UEGW2021UEGW_2253;
The ProciseDx POCT has similar accuracy but was more rapid and easy to be performed in providing the results of TDM in outpatients taking ADL. This could lead to a more rapid and effective optimization of the biological drug, thus avoiding treatment failure.
- Imraldi (adalimumab biosimilar) / Biogen, Merck (MSD), Samsung, Mundipharma, Humira (adalimumab) / Eisai, AbbVie
[VIRTUAL] LONG-TERM OUTCOMES FOLLOWING A SWITCH FROM ORIGINATOR ADALIMUMAB TO THE BIOSIMILAR SB5 (IMRALDI) IN IBD (Poster Exhibition) - Jul 20, 2021 - Abstract #UEGW2021UEGW_574;
The most common adverse event was injection site pain; these patients were successfully moved on to Amgevita providing the first data about a double biosimilar switch. Over the 24 months of this biosimilar ADA program substantial cost savings were effected.
- Humira (adalimumab) / Eisai, AbbVie
[VIRTUAL] COMPARATIVE ASSESSMENT OF ADALIMUMAB TROUGH LEVELS BETWEEN POINT-OF-CARE TESTING AND CURRENT STANDARD OF CARE (ENZYME LINKED IMMUNOSORBENT ASSAY) IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE (Poster Exhibition) - Jul 20, 2021 - Abstract #UEGW2021UEGW_422;
The ProciseDx POCT has similar accuracy but was more rapid and easy to be performed in providing the results of TDM in outpatients taking ADL. This could lead to a more rapid and effective optimization of the biological drug, thus avoiding treatment failure.
- || Solymbic (adalimumab biosimilar) / Amgen, Amjevita (adalimumab biosimilar) / Amgen, Daiichi Sankyo
Clinical, Observational data, Journal: Effectiveness and safety of adalimumab biosimilar ABP 501 in Crohn's disease: an observational study. (Pubmed Central) - Jun 30, 2021
This could lead to a more rapid and effective optimization of the biological drug, thus avoiding treatment failure. our results support ABP 501 as an effective and well-tolerated drug, with a good interchangeability with its originator for the treatment of Crohn's disease.
- || Solymbic (adalimumab biosimilar) / Amgen, Amjevita (adalimumab biosimilar) / Amgen, Daiichi Sankyo
Clinical, Journal: Effectiveness and safety of switching to adalimumab biosimilar ABP 501 in Crohn's disease. (Pubmed Central) - Jun 8, 2021
(Rev Esp Enferm Dig 2020; 112: 195-200)" demonstrate that the adalimumab biosimilar ABP 501 can determine the clinical benefit with a satisfactory safety profile until the end of follow-up in a group of patients with Crohn's disease. This result could have important practical implications as it supports the concept that a biosimilar -after the approval by the European Medicines Agency- is considered interchangeable with its originator.
- || Solymbic (adalimumab biosimilar) / Amgen, Amjevita (adalimumab biosimilar) / Amgen, Daiichi Sankyo
Clinical, Journal: Effectiveness and safety of switching to adalimumab biosimilar ABP 501 in Crohn's disease: The extrapolation concept. (Pubmed Central) - Jun 8, 2021
This result could have important practical implications as it supports the concept that a biosimilar -after the approval by the European Medicines Agency- is considered interchangeable with its originator. N/A.
- Humira (adalimumab) / Eisai, AbbVie
[VIRTUAL] A SURVEY OF RHEUMATOLOGY PATIENTS’ SATISFACTION TO SWITCHING FROM ORIGINATOR TO BIOSIMILAR AGENTS () - May 21, 2021 - Abstract #EULAR2021EULAR_3790;
Only 28% of the patients found the new device difficult to use. Overall conclusion from the study showed less than one quarter of the participants showed dissatifaction towards biosimilar and less than 12 % experienced systemic side effects and whether biosimilar could be a next cost effective biologic therapy to replace originator in future requires a longer duration of study.
- Humira (adalimumab) / Eisai, AbbVie, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
[VIRTUAL] DIFFERENCES IN DRUG SURVIVAL BETWEEN ORIGINATOR AND BIOSIMILAR PRODUCTS AMONG FIRST USERS OF EACH MOLECULE (Posters Viewing) - May 21, 2021 - Abstract #EULAR2021EULAR_2066;
Despite their identical indications and therapeutic positioning, there are some differences in the baseline characteristics between patients who start ADA, IFX and RIT and their biosimilars. There are no differences in drug survival between originator and biosimilar with the possible exception of etanercept although the observed difference should be interpreted in light of possible unmeasured or residual channeling.
- Humira (adalimumab) / Eisai, AbbVie
[VIRTUAL] COMPARISON OF THE EFFICACY AND SAFETY OF ORIGINAL AND BIOSIMILAR ADALIMUMAB MOLECULES IN CHILDHOOD RHEUMATIC DISEASES (Posters Viewing) - May 21, 2021 - Abstract #EULAR2021EULAR_2036;
There are no differences in drug survival between originator and biosimilar with the possible exception of etanercept although the observed difference should be interpreted in light of possible unmeasured or residual channeling. No significant difference was observed between the biosimilar adalimumab ABP-501 and RP adalimumab in terms of efficacy and safety.
- | Amjevita (adalimumab biosimilar) / Amgen, Daiichi Sankyo
@AmgenFrance bonjour, comment transporter Amgevita pour 9h de route? (Twitter) - May 18, 2021
- Solymbic (adalimumab biosimilar) / Amgen, Amjevita (adalimumab biosimilar) / Amgen, Daiichi Sankyo, Humira (adalimumab) / Eisai, AbbVie
[VIRTUAL] SPOSAB ABP 501 - A Sicilian Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Adalimumab Biosimilar ABP 501 (Virtual Poster Exhibition) - May 5, 2021 - Abstract #ECCOIBD2021ECCO_IBD_754;
Safety and effectiveness of ABP 501 seem to be overall similar to those reported for ADA originator. Switching from originator to ABP 501 was safe and effective.
- Imraldi (adalimumab biosimilar) / Biogen, Merck (MSD), Samsung, Mundipharma, Humira (adalimumab) / Eisai, AbbVie
[VIRTUAL] Long-term outcomes following a switch from originator adalimumab to the biosimilar SB5 (Imraldi) in IBD (Virtual Poster Exhibition) - May 5, 2021 - Abstract #ECCOIBD2021ECCO_IBD_563;
The most common adverse event was injection site pain; these patients were successfully moved on to Amgevita providing the first data about a double biosimilar switch. Over the 24 months of this biosimilar ADA program substantial cost savings were effected.
- Humira (adalimumab) / Eisai, AbbVie
[VIRTUAL] Comparative Assessment of Adalimumab Trough Levels between Point-of-Care Testing and current Standard of Care (enzyme linked immunosorbent assay) in patients with Inflammatory Bowel Disease (Virtual Poster Exhibition) - May 5, 2021 - Abstract #ECCOIBD2021ECCO_IBD_558;
Conclusion The ProciseDx POCT has similar accuracy but was more rapid and easy to be performed in providing the results of TDM in outpatients taking ADL. This could lead to a more rapid and effective optimization of the biological drug, thus avoiding treatment failure.
- ||| Amjevita (adalimumab biosimilar) / Amgen, Daiichi Sankyo
Est-ce que vous pensez qu'une personne de 18ans sous Amgevita avec spondylarthrite & crohn pourrait espérer qu'une transplantation lui soit bénéfique ? Merci pour votre attention. (Twitter) - Apr 28, 2021
- Humira (adalimumab) / Eisai, AbbVie
[VIRTUAL] Cost-Effectiveness Analysis of Adalimumab Biosimilar Compared to Delayed Biologic Treatment Initiation in Patients with Rheumatoid Arthritis in Germany () - Apr 12, 2021 - Abstract #ISPOR2021ISPOR_83;
With a cost reduction of €23,282 and incremental QALYS and LYs of 0.047 and 0.029, respectively, earlier intervention with AMGEVITA dominated later intervention with originator adalimumab. CONCLUSIONS The availability of AMGEVITA allows eligible RA patients to be treated earlier with biologics, whilst simultaneously reducing the costs of treating RA versus the originator.
- | Enrollment open: NeuMRA: Effect of Antiinflammatory Treatment Versus Hand Training on Neuropsychiatric Comorbidity in RA-patients (clinicaltrials.gov) - Apr 8, 2021
P=N/A, N=212, Recruiting, Sponsor: Vastra Gotaland Region
CONCLUSIONS The availability of AMGEVITA allows eligible RA patients to be treated earlier with biologics, whilst simultaneously reducing the costs of treating RA versus the originator. Not yet recruiting --> Recruiting
- Imraldi (adalimumab biosimilar) / Biogen, Merck (MSD), Samsung, Mundipharma, Humira (adalimumab) / Eisai, AbbVie
[VIRTUAL] LONG-TERM OUTCOMES FOLLOWING A SWITCH FROM ORIGINATOR ADALIMUMAB TO THE BIOSIMILAR SB5 (IMRALDI) IN A REAL-WORLD IBD COHORT (DDW Virtual) - Mar 15, 2021 - Abstract #DDW2021DDW_3251;
These data confirm that switching to SB5 does not affect treatment efficacy and safety. Substantial cost savings were effected as a result of this managed switch program.
- Solymbic (adalimumab biosimilar) / Amgen, Amjevita (adalimumab biosimilar) / Amgen, Daiichi Sankyo
[VIRTUAL] SPOSAB ABP 501 - A SICILIAN PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE TREATED WITH ADALIMUMAB BIOSIMILAR ABP 501 (Uncontrolled Therapeutic Observations in Humans Using Biologic or Non-Biologic Agents) - Feb 5, 2021 - Abstract #CCCongress2021CCCongress_263;
Thirty-six SAEs occurred in 36 patients [(6.4% - incidence rate (IR): 8.9 per 100 person-years (PY)]. The IR of SAEs was higher among patients in group A compared with group C (17.4 vs.
- ||| Enrollment open: FREE: De-escalation of Anti-TNF Therapy in Inflammatory Bowel Disease (clinicaltrials.gov) - Jan 27, 2021
P4, N=148, Recruiting, Sponsor: University Medical Center Groningen
The IR of SAEs was higher among patients in group A compared with group C (17.4 vs. Not yet recruiting --> Recruiting
- | Amjevita (adalimumab-atto) / Amgen, Daiichi Sankyo
Enrollment change, Trial completion date, Trial termination, Trial primary completion date, Head-to-Head: ADA-SWITCH: Loss of Response of Adalimumab Biosimilar vs Adalimumab Original, in Inflammatory Bowel Disease. (clinicaltrials.gov) - Jan 12, 2021
P4, N=24, Terminated, Sponsor: Fundaci
Not yet recruiting --> Recruiting N=216 --> 24 | Trial completion date: Jan 2021 --> Jun 2020 | Not yet recruiting --> Terminated | Trial primary completion date: Dec 2020 --> Jun 2020; Sponsor cancellation
- Amjevita (adalimumab biosimilar) / Amgen, Daiichi Sankyo
[VIRTUAL] Monocentric study in Real-life: efficacy and safety of the switch from adalimumab originator to adalimumab biosimilar in an adult population with psoriasis Vulgar () - Dec 6, 2020 - Abstract #SIDEMAST2020SIDEMAST_22;
However in the subpopulation of patients with BMI> 25, the VAS was found to be greater at 3-month follow-up compared to VAS at the time of switch. It is not possible, in the light of the available data, to rule out that this difference can be attributed at least in part to a WALNUT effect.
- || Review, Journal: Adalimumab Biosimilars in the Treatment of Rheumatoid Arthritis: A Systematic Review of the Evidence for Biosimilarity. (Pubmed Central) - Dec 3, 2020
P1, P3
Data from several switching studies showed no changes in efficacy, safety, trough serum drug concentration, or immunogenicity between the biosimilars and their RP.Trial registration: ClinicalTrials.gov identifiers: NCT02260791, NCT02405780, NCT01970475, NCT02137226, NCT02045979, NCT02744755, NCT02144714, NCT02167139, NCT03014947, NCT02114931, NCT02640612, NCT02640612, NCT02167139, NCT03052322, NCT02480153. EudraCT numbers: 2012-005140-23, 2012-000785-37, 2013-003722-84, 2015-000579-28, 2014-002879-29, 2014-000662-21, 2013-004654-13, 2015-002634-41, 2014-005229-11, 2016-002852-26, 2014-000352-29.
- | New P4 trial: FREE: De-escalation of Anti-TNF Therapy in Inflammatory Bowel Disease (clinicaltrials.gov) - Nov 26, 2020
P4, N=148, Not yet recruiting, Sponsor: University Medical Center Groningen
- | New P3 trial: Impact of Tapering Immunosuppressants on Maintaining Minimal Disease Activity in Adult Subjects With Psoriatic Arthritis (clinicaltrials.gov) - Oct 29, 2020
P3, N=270, Not yet recruiting, Sponsor: University of Erlangen-N
- | Amjevita (adalimumab biosimilar) / Amgen, Daiichi Sankyo
@AmgenBiosim Hello, where can I buy Amgevita in Palma de Mallorca or online? What are the costs? Thanks. (Twitter) - Oct 8, 2020
- [VIRTUAL] The Biosimilar Effect on Adalimumab Originator Price- The Italian Scenario () - Oct 3, 2020 - Abstract #ISPOREU2020ISPOR-EU_1825;
Our analysis shows the relevance of biosimilars from a market price perspective. While for adalimumab originator AIFA price negotiations (additional therapeutic indications) only had a limited effect, the introduction of biosimilars, due to a competitive effect, has significantly reduced the overall net price of both originator and biosimilars, with understandable benefit for iNHS spending.
- Amjevita (adalimumab biosimilar) / Amgen, Daiichi Sankyo
[VIRTUAL] Budget Impact Analysis to Assess The Impact of Adalimumab-atto (Biosimilar) Compared to Adalimumab in Autoimmune Diseases in United Arab Emirates () - Oct 3, 2020 - Abstract #ISPOREU2020ISPOR-EU_1769;
While for adalimumab originator AIFA price negotiations (additional therapeutic indications) only had a limited effect, the introduction of biosimilars, due to a competitive effect, has significantly reduced the overall net price of both originator and biosimilars, with understandable benefit for iNHS spending. The introduction of biosimilar adalimumab-atto has the potential to lead to substantial savings in the overall budget for the treatment of autoimmune disease patients from DHA payer perspective.
- Amjevita (adalimumab biosimilar) / Amgen, Daiichi Sankyo
[VIRTUAL] Cost-Effectiveness Analysis of Adalimumab Biosimilar for Rheumatoid Arthritis in Brazil Compared to Delayed Biologic Treatment Initiation () - Oct 3, 2020 - Abstract #ISPOREU2020ISPOR-EU_1558;
With a cost reduction of $196,269 and incremental QALYS and LYs of 0.05 and 0.03, respectively, as a result ICER was negative and earlier intervention with AMGEVITA™ dominated later intervention with originator adalimumab. CONCLUSIONS The availability of AMGEVITA™ has the potential to contribute to reducing the treatment costs for RA.
- | Enrollment open: Rhoneswitch: A 12-month Real Life Study of IBD Patients Switched From Adalimumab Originator Humira (clinicaltrials.gov) - Sep 28, 2020
P=N/A, N=400, Recruiting, Sponsor: University Hospital, Grenoble
CONCLUSIONS The availability of AMGEVITA™ has the potential to contribute to reducing the treatment costs for RA. Not yet recruiting --> Recruiting
- ||| Amjevita (adalimumab biosimilar) / Amgen, Daiichi Sankyo
Si seulement vous pouviez en avoir "besoin"... 18 ans en fin janvier & sous Amgevita depuis juillet... [Crohn & spondylarthrite]. Et surtout, volontaire très motivé pour des tests ! 🙏🏻 💚🍀 (Twitter) - Sep 10, 2020
- Solymbic (adalimumab biosimilar) / Amgen, Amjevita (adalimumab biosimilar) / Amgen, Daiichi Sankyo
[VIRTUAL] SPOSAB ABP 501 - A SICILIAN PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE TREATED WITH ADALIMUMAB BIOSIMILAR ABP 501 (Poster Exhibition) - Jul 19, 2020 - Abstract #UEGW2020UEGW_4637;
Safety and effectiveness of ABP 501 seem to be overall similar to those reported for ADA originator. Switching from originator to ABP 501 was safe and effective.
- Solymbic (adalimumab biosimilar) / Amgen, Amjevita (adalimumab biosimilar) / Amgen, Daiichi Sankyo
[VIRTUAL] REAL-LIFE EFFECTIVENESS AND SAFETY OF ABP501, AN ADALIMUMAB BIOSIMILAR, IN INFLAMMATORY BOWEL DISEASE: A MULTICENTER ITALIAN STUDY (Poster Exhibition) - Jul 19, 2020 - Abstract #UEGW2020UEGW_4617;
Switching from originator to ABP 501 was safe and effective. This abstract will be published on October 11, 2020
- Solymbic (adalimumab biosimilar) / Amgen, Amjevita (adalimumab biosimilar) / Amgen, Daiichi Sankyo
[VIRTUAL] SWITCHING FROM ADALIMUMAB ORIGINATOR TO ABP 501 BIOSIMILAR: A MULTICENTRIC NORTH ITALIAN STUDY (Poster Exhibition) - Jul 19, 2020 - Abstract #UEGW2020UEGW_4606;
Our data shows that after switching, 1/3 of the patients may experience a disease relapse, requiring treatment optimization (i.e. addiction of steroids or increasing the dose to once a week) or treatment discontinuation. Thus, patients should be strictly observed in order to prevent or, at least, early manage such clinical relapses.
- Solymbic (adalimumab biosimilar) / Amgen, Amjevita (adalimumab biosimilar) / Amgen, Daiichi Sankyo
[VIRTUAL] SPOSAB ABP 501 - A SICILIAN PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE TREATED WITH ADALIMUMAB BIOSIMILAR ABP 501 (Poster Exhibition) - Jul 19, 2020 - Abstract #UEGW2020UEGW_2661;
Safety and effectiveness of ABP 501 seem to be overall similar to those reported for ADA originator. Switching from originator to ABP 501 was safe and effective.
- Solymbic (adalimumab biosimilar) / Amgen, Amjevita (adalimumab biosimilar) / Amgen, Daiichi Sankyo
[VIRTUAL] REAL-LIFE EFFECTIVENESS AND SAFETY OF ABP501, AN ADALIMUMAB BIOSIMILAR, IN INFLAMMATORY BOWEL DISEASE: A MULTICENTER ITALIAN STUDY (Poster Exhibition) - Jul 19, 2020 - Abstract #UEGW2020UEGW_2641;
Switching from originator to ABP 501 was safe and effective. This abstract will be published on October 11, 2020
- Solymbic (adalimumab biosimilar) / Amgen, Amjevita (adalimumab biosimilar) / Amgen, Daiichi Sankyo
[VIRTUAL] SWITCHING FROM ADALIMUMAB ORIGINATOR TO ABP 501 BIOSIMILAR: A MULTICENTRIC NORTH ITALIAN STUDY (Poster Exhibition) - Jul 19, 2020 - Abstract #UEGW2020UEGW_2630;
Our data shows that after switching, 1/3 of the patients may experience a disease relapse, requiring treatment optimization (i.e. addiction of steroids or increasing the dose to once a week) or treatment discontinuation. Thus, patients should be strictly observed in order to prevent or, at least, early manage such clinical relapses.
- Solymbic (adalimumab biosimilar) / Amgen, Amjevita (adalimumab biosimilar) / Amgen, Daiichi Sankyo
[VIRTUAL] SPOSAB ABP 501 - A SICILIAN PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE TREATED WITH ADALIMUMAB BIOSIMILAR ABP 501 (Poster Exhibition) - Jul 19, 2020 - Abstract #UEGW2020UEGW_677;
Safety and effectiveness of ABP 501 seem to be overall similar to those reported for ADA originator. Switching from originator to ABP 501 was safe and effective.